Drug Trial Radar · NCT07950215
A Phase III Study of AND017 to Evaluate Efficacy and Safety in NDD-CKD Associated Anemia
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Feb 1, 2027
Primary completion
Dec 1, 2027
Study completion Jun 1, 2028
Sponsor
- Lead sponsor
- Kind Pharmaceuticals LLCIndustry
- Sponsor type
- Industry
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of AND017 in non-dialysis-dependent (NDD)-CKD patients with anemia compared with the active control, erythropoietin stimulating agents (ESA).
Conditions
- Anemia Due to Chronic Kidney Disease
Interventions
AND017 capsulesDrug
AND017 capsules administered orally with a starting dose of 8 mg TIW for ESA naive patients or 10 mg TIW for ESA treated patients
ESADrug
ESA injection and dose based on package insert and local practice
Primary outcomes
What the sponsor says the trial is designed to measure.
- The mean Hb levels averaged over Week 25-29Time frame: Week 25 to Week 29
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.